Related Experiment Videos
[Systemic lysotherapy using recombinant tissue plasminogen activator for fulminant pulmonary embolism]
Deutsche Medizinische Wochenschrift (1946)
|February 16, 1990
Summary
Recombinant tissue plasminogen activator (rt-PA) effectively treated massive pulmonary embolism by restoring lung perfusion. This intravenous infusion offers a safe and efficient alternative to other thrombolysis methods.
Area of Science:
- Cardiology
- Pulmonology
- Thrombolytic Therapy
Background:
- Massive pulmonary embolism (PE) poses a significant risk, often stemming from deep vein thrombosis (DVT).
- Hemodynamically significant PE necessitates prompt and effective treatment to prevent mortality and morbidity.
- Traditional treatments include systemic or selective thrombolysis and surgical embolectomy, each with associated risks.
Observation:
- A 44-year-old female presented with massive PE secondary to DVT.
- Initial perfusion scintigraphy revealed complete right lung avascularity and segmental defects in the left lung.
- Echocardiographic and electrocardiographic findings indicated acute right heart strain.
Findings:
- Intravenous infusion of recombinant tissue plasminogen activator (rt-PA) was administered over two hours.
- Hemodynamic status, right heart strain indicators, and arterial oxygenation (pO2) improved during rt-PA infusion.
- Post-treatment scintigraphy at 48 hours demonstrated near-complete reperfusion of both lungs.
Implications:
- Intravenous rt-PA infusion is a potentially effective and low-risk treatment for hemodynamically significant massive PE.
- This approach may offer advantages over conventional thrombolytic agents (urokinase, streptokinase) and surgical embolectomy.
- Further research into rt-PA for massive PE could refine treatment protocols and improve patient outcomes.